Johnson & Johnson kept at market perform by JMP

JMP Securities analyst Robert C. Faulkner maintained Johnson & Johnson at market perform. The company's 2008/2009 sales growth outlook is poor and carries substantial risk. The risk includes approval of dapoxetine and the performance of paliperidone, Ionsys and Prezista. JMP raised its 2006 earnings per share to $3.69 from $3.67. Shares of the New Brunswick, N.J.-based pharmaceutical company were up 71 cents, or 1.17%, at $61.31 on volume of 8,465,000 shares versus the three-month running average of 8,638,230 shares. (NYSE: JNJ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.